Investigational Drug Details
| Drug ID: | D227 |
| Drug Name: | Pentoxifylline |
| Synonyms: | |
| Type: | small molecule |
| DrugBank ID: | DB00806 |
| DrugBank Description: | A methylxanthine derivative that inhibits phosphodiesterase and affects blood rheology. It improves blood flow by increasing erythrocyte and leukocyte flexibility. It also inhibits platelet aggregation. Pentoxifylline modulates immunologic activity by stimulating cytokine production. [PubChem] |
| PubChem ID: | 4740 |
| CasNo: | 6493-05-6 |
| Repositioning for NAFLD: | Yes |
| SMILES: | CN1C=NC2=C1C(=O)N(CCCCC(C)=O)C(=O)N2C |
| Structure: |
|
| InChiKey: | BYPFEZZEUUWMEJ-UHFFFAOYSA-N |
| Molecular Weight: | 278.307 |
| DrugBank Targets: | Adenosine receptor A2a; NA; Adenosine receptor A1; 5'-nucleotidase |
| DrugBank MoA: | Pentoxifylline inhibits erythrocyte phosphodiesterase, resulting in an increase in erythrocyte cAMP activity. Subsequently, the erythrocyte membrane becomes more resistant to deformity. Along with erythrocyte activity, pentoxifylline also decreases blood viscosity by reducing plasma fibrinogen concentrations and increasing fibrinolytic activity. It is also a non selective adenosine receptor antagonist. |
| DrugBank Pharmacology: | Pentoxifylline, a synthetic dimethylxanthine derivative structurally related to theophylline and caffeine, is used in the treatment of peripheral vascular diseases and in the management of cerebrovascular insufficiency, sickle cell disease, and diabetic neuropathy. |
| DrugBank Indication: | For the treatment of patients with intermittent lameness or immobility arising from chronic occlusive arterial disease of the limbs. |
| Targets: | |
| Therapeutic Category: | |
| Clinical Trial Progress: | |
| Latest Progress: |
| Trial ID | Source ID | Phases | Status | Study Results | Start Date | Last Update Posted | |
|---|---|---|---|---|---|---|---|
| L0054 | NCT00338000 | PHASE4 | COMPLETED | NO | 2001-06 | 2011-02-01 | Details |
| L0122 | NCT00139035 | PHASE4 | COMPLETED | NO | 2005-04 | 2012-11-02 | Details |
| L0133 | NCT01453192 | PHASE3 | COMPLETED | NO | 2011-12 | 2016-07-12 | Details |
| L0351 | NCT04917718 | PHASE4 | UNKNOWN | NO | 2021-08-16 | 2022-04-13 | Details |
| L0368 | NCT00433342 | PHASE1 | TERMINATED | NO | 2006-03 | 2020-04-27 | Details |
| L0710 | NCT00786136 | PHASE4 | COMPLETED | NO | 2008-12 | 2013-04-10 | Details |
| L1277 | NCT04667533 | PHASE1 | COMPLETED | NO | 2020-11-11 | 2022-05-18 | Details |
| L2105 | NCT01842620 | PHASE4 | COMPLETED | YES | 2013-03-13 | 2017-12-22 | Details |
| L2660 | NCT00469092 | PHASE4 | COMPLETED | YES | 2007-05 | 2017-02-23 | Details |
| L3404 | NCT03510624 | PHASE1 | COMPLETED | NO | 2018-11-09 | 2021-04-28 | Details |
| L3584 | NCT00046501 | PHASE3 | COMPLETED | NO | 2002-11 | 2011-01-11 | Details |
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|
| Article ID | PMID | Source | Title |
|---|